杜皮鲁玛
医学
特应性皮炎
葡萄膜炎
皮肤病科
四分位间距
免疫学
内科学
作者
Roselie Achten,Chantal van Luijk,Judith L. Thijs,Julia Drylewicz,Eveline M. Delemarre,Stefan Nierkens,Daphne Bakker,Femke van Wijk,Marlies de Graaf,Marjolein de Bruin‐Weller,Joke de Boer,Jonas J.W. Kuiper
标识
DOI:10.1080/09273948.2023.2182325
摘要
Severe uveitis is a rare complication of interleukin-4 receptor alpha blocking by dupilumab in topic dermatitis (AD) patients. The aim of this study was to describe five moderate-to-severe AD patients who developed uveitis during dupilumab treatment and to compare the proteomic profile of aqueous humor (AqH) of dupilumab-associated uveitis (n=3/5 available samples) with non-infectious uveitis (n=27) and cataract controls (n=11). Included patients were treated at the University Medical Center Utrecht (the Netherlands). Active dupilumab-associated uveitis complicated by serous detachment, cystoid macular edema, or secondary glaucoma developed within a median of 6.0 months (interquartile range 2.3-16.5 months) after starting dupilumab. Uveitis resolved after discontinuation of dupilumab and/or treatment with local or systemic corticosteroids. Proteomic profiling of AqH revealed that the molecular profile of dupilumab-associated uveitis resembled that of non-infectious uveitis. In conclusion, dupilumab-associated uveitis is a severe adverse event of dupilumab therapy, requiring urgent referral to an ophthalmologist.
科研通智能强力驱动
Strongly Powered by AbleSci AI